Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to subcutaneous administration, offering shorter injection times, home use, and cost savings for cancer, Alzheimer’s, and inflammatory diseases.
A recent study revealed that patients with hidradenitis suppurativa experience quicker treatment failure when switching to biosimilar adalimumab compared to the original.
A new report reveals the heavy personal and economic toll of MS and recommends more complete, patient focused approaches to measuring and managing the disease.
Kamuvudines are a new class of drugs that are derived from the anti-HIV nucleoside reverse transcriptase inhibitors. They are designed to inhibit the inflammasome, part of the innate immune system that is triggered in geographic atrophy.
CMS has released the negotiated prices for the second set of drugs for Medicare Part D through the Inflation Reduction Act. Discounts range from 38% for Austedo and Austedo XR to 85% for Janumet and Janumet XR.
Ralph Abraham's appointment as CDC's principal deputy director raises concerns over vaccine trust and public health amid political pressures and misinformation.
Telehealth mostly replaces in-person visits, with a 74% substitution rate, indicating lower federal costs and sustained value beyond the pandemic.
Itvisma is a one-time gene therapy approved for both children and adults with spinal muscular atrophy. It will be available in December.
A provision in the One Big Beautiful Bill delays or exempts high-spending medications with orphan indications from Medicare drug price negotiations.
A new blood test and app combination enhances tuberculosis screening in China, enabling early detection and cost-effective solutions in resource-limited areas.
ASTRO's new guidelines enhance radiation therapy strategies for gastric cancer, improving treatment outcomes and patient care across various stages of the disease.
Nicotine dependency is a worldwide health threat, especially for HIV patients, who are more likely to smoke and to have health complications than healthy patients.
Beginning in January 2026, Optum Rx is removing reauthorizations for two new drug classes: hormone therapies and knee osteoarthritis injectables.
Here’s what you missed this week on Managed Healthcare Executive.
Public health experts express concern over the CDC's revised vaccine-autism webpage, warning it may fuel mistrust and confusion about vaccine safety.
GLP-1 receptor agonists significantly lower five-year mortality in highly obese colon cancer patients, highlighting potential benefits beyond weight loss and inflammation reduction.
This year marks the fifth consecutive year Independence Blue Shield has received high marks for their Medicare plans.
A new report says complications such as severe encephalitis and Ramsay Hunt Syndrome are among the reasons people with shingles have extended hospital stays.
A pilot program limiting the patient co-pay to $50 could burden Part D plans, depending on whether manufacturers discount their prices — and by how much.
The patch measures distinct electrical patterns, which indicates how easily electrical signals pass through living tissue. Cancerous areas have different electrical properties than healthy skin.
The CDC's recent update on vaccines and autism sparks confusion, raising concerns about public trust and the implications for vaccine safety.
Eylea HD offers two dosing options for patients with retinal vein occlusion: 8-week and 4-week dosing intervals.
The results of a new Kinsey Institute study show that masturbation eased menopause symptoms for a significant number of women, yet few clinicians discuss it, despite strong interest from patients.
The American Gastroenterological Association has released updated guidelines for treating moderate-to-severe Crohn’s disease, outlining 16 evidence-based recommendations that prioritize advanced therapies and reflect new medication approvals since 2021.
Promising new medications for resistant gonorrhea, such as zoliflodacin and gepotidacin, are waiting for FDA approval, and they offer hope for effective treatment options.
Viral infections such as COVID-19, HIV and hepatitis C significantly elevate cardiovascular disease risks, highlighting the importance of vaccination and preventive strategies.
Mark Nestor reveals groundbreaking insights on botulinum toxin's evolving science, enhancing its efficacy and expanding its medical applications in dermatology.
Health benefit costs for employees are projected to rise 6.7% in 2026—the largest increase in 15 years—as employers grapple with escalating prescription drug prices, growing GLP-1 coverage and a broader push to offer diverse, cost-saving health plan options amid mounting affordability concerns.
Tumor infiltrating lymphocyte (TIL) therapy uses immune cells harvested directly from a patient’s tumor.
